This announcement is a separate document:
エーザイ：抗体薬物複合体farletuzumab ecteribulin（FZEC）に関して、エーザイ単独でのグローバル開発・商業化に移行
Eisai: Regarding the antibody drug complex farletuzumab ecteribulin (FZEC), Eisai will transition to global development and commercialization on its own.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.